BioCentury
ARTICLE | Company News

Cuban Center for Genetic Engineering and Biotechnology (CIGB), Truffle Capital infectious, cancer news

February 24, 2014 8:00 AM UTC

Truffle Capital launched Abivax S.A.S. (Paris, France) to develop therapeutic vaccines and antivirals to treat infectious diseases and cancer. Truffle merged three companies financed by Truffle - Splicos S.A.S., Wittycell S.A.S. and Zophis - to form Abivax. The newco also signed an exclusive deal with CIGB to co-develop a therapeutic vaccine from Wittycell and CIGB in Phase IIb testing to treat chronic HBV infection. Abivax has rights to commercialize the vaccine. The partners did not disclose financial terms. ...